Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Julio Delgado et al.|New England Journal of Medicine|2014Cited by 1.6k
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation studyAdrian Bloor, Amit Patel, James E. Griffin et al.|Nature Medicine|2020Cited by 289
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79
<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A. Eyre, Anna Schuh, Ruth Clifford et al.|British Journal of Haematology|2016Cited by 66